<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>4</IssueIDStart>
          <IssueIDEnd>4</IssueIDEnd>
          <IssueArticleCount>15</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>12</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2006</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art4">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>74820</ArticleID>
            <ArticleDOI>10.1208/aapsj070479</ArticleDOI>
            <ArticleSequenceNumber>4</ArticleSequenceNumber>
            <ArticleTitle Language="En">Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems</ArticleTitle>
            <ArticleFirstPage>E820</ArticleFirstPage>
            <ArticleLastPage>E833</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>9</Month>
                <Day>2</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>9</Month>
                <Day>23</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>4</IssueIDStart>
              <IssueIDEnd>4</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Nicholas</GivenName>
                  <FamilyName>Bodor</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(352) 392-3417</Phone>
                  <Fax>(352) 392-8589</Fax>
                  <Email>bodor@cop.ufl.edu</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Peter</GivenName>
                  <FamilyName>Buchwald</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Center for Drug Discovery</OrgDivision>
                <OrgName>University of Florida, Health Science Center</OrgName>
                <OrgAddress>
                  <Postbox>PO Box 100497</Postbox>
                  <Postcode>32610-0497</Postcode>
                  <City>Gainesville</City>
                  <State>FL</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgName>IVAX Research Inc</OrgName>
                <OrgAddress>
                  <Street>4400 Biscayne Blvd</Street>
                  <Postcode>33137</Postcode>
                  <City>Miami</City>
                  <State>FL</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>Despite its apparent easy accessibility, the eye is, in fact, well protected against the absorption of foreign materials, including therapeutic agents, by the eyelids, by the tearflow, and by the permeability barriers imposed by the cornea on one side and the blood-retinal barrier on the other. Most existing ophthalmic drugs were adapted from other therapeutic applications and were not specifically developed for the treatment of eye diseases; hence, they are not well suited to provide eye-specific effects without causing systemic side effects. A real breakthrough in the area of ophthalmic therapeutics can be achieved only by specifically designing new drugs for ophthalmic applications to incorporate the possibility of eye targeting into their chemical structure. Possibilities provided along these lines by designing chemical delivery systems (CDSs) and soft drugs within the framework of retrometabolic drug design are reviewed here. Both are general concept applicable in almost any therapeutic area. This review will concentrate on \-adrenergic agonists and anti-inflammatory corticosteroids, where clinical results obtained with new chemical entities, such as betaxoxime, adaprolol, loteprednol etabonate, and etiprednol dicloacetate, exist to support the advantages of such metabolism-focused, ophthalmic-specific drug design approaches.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>beta-blockers</Keyword>
              <Keyword>corticosteroids</Keyword>
              <Keyword>eye-targeted delivery</Keyword>
              <Keyword>glaucoma</Keyword>
              <Keyword>intraocular pressure</Keyword>
              <Keyword>oxime</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: December 7, 2005.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_74820.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Stewart</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>UI</Initials>
                    <FamilyName>Tuor</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Blood-eye barriers in the rat: correlation of ultrastructure with function</ArticleTitle>
                  <JournalTitle>J Comp Neurol</JournalTitle>
                  <VolumeID>340</VolumeID>
                  <FirstPage>566</FirstPage>
                  <LastPage>576</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8006217</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/cne.903400409</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK2c3nsV2hug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stewart PA, Tuor UI. Blood-eye barriers in the rat: correlation of ultrastructure with function.<Emphasis Type="Italic">J Comp Neurol</Emphasis>. 1994;340:566–576.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RD</Initials>
                    <FamilyName>Schoenwald</FamilyName>
                  </BibAuthorName>
                  <Year>1990</Year>
                  <ArticleTitle Language="En">Ocular drug delivery: pharmacokinetic considerations</ArticleTitle>
                  <JournalTitle>Clin Pharmacokinet</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>255</FirstPage>
                  <LastPage>269</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2182264</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00003088-199018040-00001</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3c3hsVSlsw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schoenwald RD. Ocular drug delivery: pharmacokinetic considerations.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1990;18:255–269.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Mitra</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TJ</Initials>
                    <FamilyName>Mikkelson</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Mechanism of transcorneal permeation of pilocarpine</ArticleTitle>
                  <JournalTitle>J Pharm Sci</JournalTitle>
                  <VolumeID>77</VolumeID>
                  <FirstPage>771</FirstPage>
                  <LastPage>775</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3225772</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/jps.2600770911</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXls1aru78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1988;77:771–775.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NM</Initials>
                    <FamilyName>Davies</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Biopharmaceutical considerations in topical ocular drug delivery</ArticleTitle>
                  <JournalTitle>Clin Exp Pharmacol Physiol</JournalTitle>
                  <VolumeID>27</VolumeID>
                  <FirstPage>558</FirstPage>
                  <LastPage>562</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10874518</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1440-1681.2000.03288.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXkt12lsLc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Davies NM. Biopharmaceutical considerations in topical ocular drug delivery.<Emphasis Type="Italic">Clin Exp Pharmacol Physiol</Emphasis>. 2000;27:558–562.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GM</Initials>
                    <FamilyName>Grass</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Robinson</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Mechanism of corneal penetration. I. In vivo and in vitro kinetics</ArticleTitle>
                  <JournalTitle>J Pharm Sci</JournalTitle>
                  <VolumeID>77</VolumeID>
                  <FirstPage>3</FirstPage>
                  <LastPage>14</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3126290</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/jps.2600770103</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXktVShsb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Grass GM, Robinson JR. Mechanism of corneal penetration. I. In vivo and in vitro kinetics.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1988;77:3–14.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MR</Initials>
                    <FamilyName>Prausnitz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Noonan</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Permeability of cornea, sclera, and conjuctiva: a literature analysis for drug delivery to the eye</ArticleTitle>
                  <JournalTitle>J Pharm Sci</JournalTitle>
                  <VolumeID>87</VolumeID>
                  <FirstPage>1479</FirstPage>
                  <LastPage>1488</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10189253</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/js9802594</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXmsFKku74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjuctiva: a literature analysis for drug delivery to the eye.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1998;87:1479–1488.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Edwards</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MR</Initials>
                    <FamilyName>Prausnitz</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Predicted permeability of the cornea to topical drugs</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>1497</FirstPage>
                  <LastPage>1508</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1013061926851</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXos1aqu78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Edwards A, Prausnitz MR. Predicted permeability of the cornea to topical drugs.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2001;18:1497–1508.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>VH</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Robinson</FamilyName>
                  </BibAuthorName>
                  <Year>1986</Year>
                  <ArticleTitle Language="En">Topical ocular drug delivery: recent developments and future challenges</ArticleTitle>
                  <JournalTitle>J Ocul Pharmacol</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>67</FirstPage>
                  <LastPage>108</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3332284</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL28XkvVCqtbg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/jop.1986.2.67</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges.<Emphasis Type="Italic">J Ocul Pharmacol</Emphasis>. 1986;2:67–108.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Sasaki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Yamamura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Mukai</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Enhancement of ocular drug penetration</ArticleTitle>
                  <JournalTitle>Crit Rev Ther Drug Carrier Syst</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>85</FirstPage>
                  <LastPage>146</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10099899</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXitFCjsrk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sasaki H, Yamamura K, Mukai T, et al. Enhancement of ocular drug penetration.<Emphasis Type="Italic">Crit Rev Ther Drug Carrier Syst</Emphasis>. 1999;16:85–146.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibBook>
                  <BibEditorName>
                    <Initials>H</Initials>
                    <FamilyName>Bundgaard</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <Year>1985</Year>
                  <BookTitle>Design of Prodrugs</BookTitle>
                  <PublisherName>Elsevier Science</PublisherName>
                  <PublisherLocation>Amsterdam, The Netherlands</PublisherLocation>
                </BibBook>
                <BibUnstructured>Bundgaard H, ed.<Emphasis Type="Italic">Design of Prodrugs</Emphasis>. Amsterdam, The Netherlands: Elsevier Science; 1985.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JJ</Initials>
                    <FamilyName>Kaminski</FamilyName>
                  </BibAuthorName>
                  <Year>1987</Year>
                  <ArticleTitle Language="En">Prodrugs and site-specific chemical delivery systems</ArticleTitle>
                  <JournalTitle>Annu Rep Med Chem</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>303</FirstPage>
                  <LastPage>313</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXnsA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Kaminski JJ. Prodrugs and site-specific chemical delivery systems.<Emphasis Type="Italic">Annu Rep Med Chem</Emphasis>. 1987;22:303–313.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>CG</Initials>
                    <FamilyName>Wermuth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J-C</Initials>
                    <FamilyName>Gaignault</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Marchandeau</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ChapterTitle Language="En">Designing prodrugs and bioprecursors I: Carrier prodrugs</ChapterTitle>
                  <BibEditorName>
                    <Initials>CG</Initials>
                    <FamilyName>Wermuth</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>The Practice of Medicinal Chemistry</BookTitle>
                  <PublisherName>Academic Press</PublisherName>
                  <PublisherLocation>London, UK</PublisherLocation>
                  <FirstPage>671</FirstPage>
                  <LastPage>696</LastPage>
                </BibChapter>
                <BibUnstructured>Wermuth CG, Gaignault J-C, Marchandeau C. Designing prodrugs and bioprecursors I: Carrier prodrugs. In: Wermuth CG, ed.<Emphasis Type="Italic">The Practice of Medicinal Chemistry</Emphasis>. London, UK: Academic Press; 1996:671–696.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Ettmayer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GL</Initials>
                    <FamilyName>Amidon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Clement</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Testa</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Lessons learned from marketed and investigational prodrugs</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>47</VolumeID>
                  <FirstPage>2393</FirstPage>
                  <LastPage>2404</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15115379</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm0303812</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXjtVSqsbY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs.<Emphasis Type="Italic">J Med Chem</Emphasis>. 2004;47:2393–2404.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Drug targeting and retrom etabolic drug design approaches</ArticleTitle>
                  <JournalTitle>Adv Drug Deliv Rev</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>157</FirstPage>
                  <LastPage>166</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0169-409X(94)90036-1</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXkvFWgu7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N. Drug targeting and retrom etabolic drug design approaches.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 1994;14:157–166.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Buchwald</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Drug targeting via retrometabolic approaches</ArticleTitle>
                  <JournalTitle>Pharmacol Ther</JournalTitle>
                  <VolumeID>76</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>27</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9535166</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0163-7258(97)00098-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXlsVGg</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N. Buchwald P. Drug targeting via retrometabolic approaches.<Emphasis Type="Italic">Pharmacol Ther</Emphasis>. 1997;76:1–27.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Buchwald</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ChapterTitle Language="En">Retrometabolism-based drug design and targeting</ChapterTitle>
                  <BibEditorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Abraham</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Drug Discovery and Drug Development. Burger’s Medicinal Chemistry and Drug Discovery</BookTitle>
                  <EditionNumber>6th ed.</EditionNumber>
                  <PublisherName>John Wiley and Sons</PublisherName>
                  <PublisherLocation>New York, NY</PublisherLocation>
                  <FirstPage>533</FirstPage>
                  <LastPage>608</LastPage>
                </BibChapter>
                <BibUnstructured>Bodor N, Buchwald P. Retrometabolism-based drug design and targeting. In: Abraham DJ, ed.<Emphasis Type="Italic">Drug Discovery and Drug Development. Burger’s Medicinal Chemistry and Drug Discovery</Emphasis>. Vol 2. 6th ed. New York, NY: John Wiley and Sons; 2003:533–608.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>El-Koussi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Kano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Nakamuro</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for β-adrenergic blocking agents</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>100</FirstPage>
                  <LastPage>106</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2891852</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm00396a015</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXjslOguw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, El-Koussi A, Kano M, Nakamuro T. Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for β-adrenergic blocking agents.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1988;31:100–106.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>El-Koussi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1989</Year>
                  <ArticleTitle Language="En">Formation of propanolol in the iris-ciliary body from its propranolol ketoxime precursor—a potential antiglaucoma drug</ArticleTitle>
                  <JournalTitle>Int J Pharm</JournalTitle>
                  <VolumeID>53</VolumeID>
                  <FirstPage>189</FirstPage>
                  <LastPage>194</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0378-5173(89)90312-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1MXlvVSmtLs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>El-Koussi A, Bodor N. Formation of propanolol in the iris-ciliary body from its propranolol ketoxime precursor—a potential antiglaucoma drug.<Emphasis Type="Italic">Int J Pharm</Emphasis>. 1989;53:189–194.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Prokai</FamilyName>
                  </BibAuthorName>
                  <Year>1990</Year>
                  <ArticleTitle Language="En">Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>723</FirstPage>
                  <LastPage>725</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1975690</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1015863521513</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3cXlvFOkur8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Prokai L. Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1990;7:723–725.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>El-Koussi</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime—a new potential antiglaucoma agent</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>1389</FirstPage>
                  <LastPage>1395</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1798675</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1015849123020</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38XmvFE%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, El-Koussi A. Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime—a new potential antiglaucoma agent.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1991;8:1389–1395.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Simay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Prokai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1989</Year>
                  <ArticleTitle Language="En">Oxidation of aryloxy-β-amino alcohols with activated dimethylsulfoxide: a novel C-N oxidation facilitated by neighboring group effect</ArticleTitle>
                  <JournalTitle>Tetrahedron</JournalTitle>
                  <VolumeID>45</VolumeID>
                  <FirstPage>4091</FirstPage>
                  <LastPage>4102</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0040-4020(01)81305-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3cXhtFygtbs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Simay A, Prokai L, Bodor N. Oxidation of aryloxy-β-amino alcohols with activated dimethylsulfoxide: a novel C-N oxidation facilitated by neighboring group effect.<Emphasis Type="Italic">Tetrahedron</Emphasis>. 1989;45:4091–4102.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Simay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ChapterTitle Language="En">Site- and stereospecific drug delivery to the eye</ChapterTitle>
                  <BibEditorName>
                    <Initials>S</Initials>
                    <FamilyName>Sarel</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>R</Initials>
                    <FamilyName>Mechoulam</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>I</Initials>
                    <FamilyName>Agranat</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Trends in Medicinal Chemistry ’90</BookTitle>
                  <PublisherName>Blackwell Scientific Publications</PublisherName>
                  <PublisherLocation>Oxford, UK</PublisherLocation>
                  <FirstPage>361</FirstPage>
                  <LastPage>368</LastPage>
                </BibChapter>
                <BibUnstructured>Simay A, Bodor N. Site- and stereospecific drug delivery to the eye. In: Sarel S, Mechoulam R, Agranat I, eds.<Emphasis Type="Italic">Trends in Medicinal Chemistry ’90</Emphasis>. Oxford, UK: Blackwell Scientific Publications; 1992:361–368.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Retrometabolic drug design concepts in ophthalmic targetspecific drug delivery</ArticleTitle>
                  <JournalTitle>Adv Drug Deliv Rev</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>21</FirstPage>
                  <LastPage>38</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0169-409X(95)00011-U</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXotFCnsL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N. Retrometabolic drug design concepts in ophthalmic targetspecific drug delivery.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 1995;16:21–38.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Polgar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular β-blocker, in dogs</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>56</VolumeID>
                  <FirstPage>1207</FirstPage>
                  <LastPage>1213</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7475898</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0024-3205(95)00060-J</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXktVSisbo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Polgar P, Bodor N. Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular β-blocker, in dogs.<Emphasis Type="Italic">Life Sci</Emphasis>. 1995;56:1207–1213.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Prokai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Somogyi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Ocular delivery of the β-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analog</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>2018</FirstPage>
                  <LastPage>2020</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7783133</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm00011a021</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXls1yqtrk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Prokai L, Wu W-M, Somogyi G, Bodor N. Ocular delivery of the β-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analog.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1995;38:2018–2020.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HH</Initials>
                    <FamilyName>Farag</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Somogyi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MDC</Initials>
                    <FamilyName>Barros</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Prokai</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs</ArticleTitle>
                  <JournalTitle>J Ocul Pharmacol</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>389</FirstPage>
                  <LastPage>403</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXmsFektLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Farag HH, Somogyi G, Wu W-M, Barros MDC, Prokai L. Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs.<Emphasis Type="Italic">J Ocul Pharmacol</Emphasis>. 1997;13:389–403.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HH</Initials>
                    <FamilyName>Farag</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MDC</Initials>
                    <FamilyName>Barros</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Somogyi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Prokai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Ocular-specific chemical delivery system of betaxolol for safe local treatment of glaucoma</ArticleTitle>
                  <JournalTitle>Drug Des Discov</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>117</FirstPage>
                  <LastPage>130</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9342554</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXmtlGgt7c%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Farag HH, Wu W-M, Barros MDC, Somogyi G, Prokai L, Bodor N. Ocular-specific chemical delivery system of betaxolol for safe local treatment of glaucoma.<Emphasis Type="Italic">Drug Des Discov</Emphasis>. 1997;15:117–130.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Nathanson</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Stereospecificity of beta adrenergic antagonists: R-enantiomers show increased selectivity for beta-2 receptors in ciliary process</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>245</VolumeID>
                  <FirstPage>94</FirstPage>
                  <LastPage>101</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2896241</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXktlWmt78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nathanson JA. Stereospecificity of beta adrenergic antagonists: R-enantiomers show increased selectivity for beta-2 receptors in ciliary process.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1988;245:94–101.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Mehvar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DR</Initials>
                    <FamilyName>Brocks</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans</ArticleTitle>
                  <JournalTitle>J Pharm Pharm Sci</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>185</FirstPage>
                  <LastPage>200</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11466176</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXnsFygsrc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.<Emphasis Type="Italic">J Pharm Pharm Sci</Emphasis>. 2001;4:185–200.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NA</Initials>
                    <FamilyName>Sharif</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SX</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JY</Initials>
                    <FamilyName>Crider</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>McLaughlin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TL</Initials>
                    <FamilyName>Davis</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes</ArticleTitle>
                  <JournalTitle>J Ocul Pharmacol Ther</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>305</FirstPage>
                  <LastPage>317</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11572462</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/108076801753162726</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXntFWnt7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes.<Emphasis Type="Italic">J Ocul Pharmacol Ther</Emphasis>. 2001;17:305–317.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>FS</Initials>
                    <FamilyName>Nandel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RK</Initials>
                    <FamilyName>Dhaliwal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Singh</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Modeling, design, chiral aspects and role of para-substituents in aryloxypropranolamine based beta-blockers</ArticleTitle>
                  <JournalTitle>Indian J Biochem Biophys</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>29</FirstPage>
                  <LastPage>35</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10549157</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXjvFOis7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nandel FS, Dhaliwal RK, Singh B. Modeling, design, chiral aspects and role of para-substituents in aryloxypropranolamine based beta-blockers.<Emphasis Type="Italic">Indian J Biochem Biophys</Emphasis>. 1999;36:29–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibUnstructured>Quigley H. How common is glaucoma worldwide?<Emphasis Type="Italic">Int Glaucoma Rev</Emphasis> [serial online]. 2002; Available at: http://www.glaucom.com/Mettings/3-3/worldwide.php. Accessed August 16, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>SE</Initials>
                    <FamilyName>Moroi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PR</Initials>
                    <FamilyName>Lichter</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ChapterTitle Language="En">Ocular pharmacology</ChapterTitle>
                  <BibEditorName>
                    <Initials>JG</Initials>
                    <FamilyName>Hardman</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>LE</Initials>
                    <FamilyName>Limbird</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Goodman &amp; Gilman’s The Pharmacological Basis of Therapeutics</BookTitle>
                  <PublisherName>McGraw-Hill</PublisherName>
                  <PublisherLocation>New York, NY</PublisherLocation>
                  <FirstPage>1619</FirstPage>
                  <LastPage>1645</LastPage>
                </BibChapter>
                <BibUnstructured>Moroi SE, Lichter PR. Ocular pharmacology. In: Hardman JG, Limbird LE, eds.<Emphasis Type="Italic">Goodman &amp; Gilman’s The Pharmacological Basis of Therapeutics</Emphasis>. New York, NY: McGraw-Hill; 1996:1619–1645.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WL</Initials>
                    <FamilyName>Alward</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Biomedicine: a new angle on ocular development</ArticleTitle>
                  <JournalTitle>Science</JournalTitle>
                  <VolumeID>299</VolumeID>
                  <FirstPage>1527</FirstPage>
                  <LastPage>1528</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12624251</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1126/science.1082933</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjtFahsbg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Alward WL. Biomedicine: a new angle on ocular development.<Emphasis Type="Italic">Science</Emphasis>. 2003;299:1527–1528.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RL</Initials>
                    <FamilyName>Radius</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GR</Initials>
                    <FamilyName>Diamond</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IP</Initials>
                    <FamilyName>Pollack</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Langham</FamilyName>
                  </BibAuthorName>
                  <Year>1978</Year>
                  <ArticleTitle Language="En">Timolol: a new drug for management of chronic simple glaucoma</ArticleTitle>
                  <JournalTitle>Arch Ophthalmol</JournalTitle>
                  <VolumeID>96</VolumeID>
                  <FirstPage>1003</FirstPage>
                  <LastPage>1008</LastPage>
                  <Occurrence Type="PID">
                    <Handle>655936</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaE1c7os1akuw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Radius RL, Diamond GR, Pollack IP, Langham ME. Timolol: a new drug for management of chronic simple glaucoma.<Emphasis Type="Italic">Arch Ophthalmol</Emphasis>. 1978;96:1003–1008.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MF</Initials>
                    <FamilyName>Sugrue</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">New approaches to antiglaucoma therapy</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>2793</FirstPage>
                  <LastPage>2809</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9288160</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm9608725</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXlt1Kks70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sugrue MF. New approaches to antiglaucoma therapy.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1997;40:2793–2809.</BibUnstructured>
              </Citation>
              <Citation ID="CR37">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RL</Initials>
                    <FamilyName>Stamper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Wigginton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Higginbotham</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Primary drug treatment for glaucoma: beta-blockers versus other medications</ArticleTitle>
                  <JournalTitle>Surv Ophthalmol</JournalTitle>
                  <VolumeID>47</VolumeID>
                  <FirstPage>63</FirstPage>
                  <LastPage>73</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11801272</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0039-6257(01)00286-7</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stamper RL, Wigginton SA, Higginbotham EJ. Primary drug treatment for glaucoma: beta-blockers versus other medications.<Emphasis Type="Italic">Surv Ophthalmol</Emphasis>. 2002;47:63–73.</BibUnstructured>
              </Citation>
              <Citation ID="CR38">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Taniguchi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Kitazawa</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">The potential systemic effect of topically applied beta-blockers in glaucoma therapy</ArticleTitle>
                  <JournalTitle>Curr Opin Ophthalmol</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>55</FirstPage>
                  <LastPage>58</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10168358</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00055735-199704000-00010</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK2szmtlWjtQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy.<Emphasis Type="Italic">Curr Opin Ophthalmol</Emphasis>. 1997;8:55–58.</BibUnstructured>
              </Citation>
              <Citation ID="CR39">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Hayreh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Podhajsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MB</Initials>
                    <FamilyName>Zimmerman</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Beta-blocker eyedrops and nocturnal arterial hypotension</ArticleTitle>
                  <JournalTitle>Am J Ophthalmol</JournalTitle>
                  <VolumeID>128</VolumeID>
                  <FirstPage>301</FirstPage>
                  <LastPage>309</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10511024</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0002-9394(99)00160-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXmt1Wlt7Y%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1999;128:301–309.</BibUnstructured>
              </Citation>
              <Citation ID="CR40">
                <CitationNumber>40.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WL</Initials>
                    <FamilyName>Nelson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FT</Initials>
                    <FamilyName>Fraunfelder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Sills</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JB</Initials>
                    <FamilyName>Arrowsmith</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JN</Initials>
                    <FamilyName>Kuritsky</FamilyName>
                  </BibAuthorName>
                  <Year>1986</Year>
                  <ArticleTitle Language="En">Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985</ArticleTitle>
                  <JournalTitle>Am J Ophthalmol</JournalTitle>
                  <VolumeID>102</VolumeID>
                  <FirstPage>606</FirstPage>
                  <LastPage>611</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3777080</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL2s%2Fks1aguw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1986;102:606–611.</BibUnstructured>
              </Citation>
              <Citation ID="CR41">
                <CitationNumber>41.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MG</Initials>
                    <FamilyName>Lynch</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Whitson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RH</Initials>
                    <FamilyName>Brown</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Nguyen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MM</Initials>
                    <FamilyName>Drake</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Topical β-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol</ArticleTitle>
                  <JournalTitle>Arch Ophthalmol</JournalTitle>
                  <VolumeID>106</VolumeID>
                  <FirstPage>908</FirstPage>
                  <LastPage>911</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2898932</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL1c3mvVGjug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical β-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol.<Emphasis Type="Italic">Arch Ophthalmol</Emphasis>. 1988;106:908–911.</BibUnstructured>
              </Citation>
              <Citation ID="CR42">
                <CitationNumber>42.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>FT</Initials>
                    <FamilyName>Fraunfelder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Meyer</FamilyName>
                  </BibAuthorName>
                  <Year>1985</Year>
                  <ArticleTitle Language="En">Sexual dysfunction secondary to topical ophthalmic timolol</ArticleTitle>
                  <JournalTitle>JAMA</JournalTitle>
                  <VolumeID>253</VolumeID>
                  <FirstPage>3092</FirstPage>
                  <LastPage>3093</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3999290</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1001/jama.253.21.3092</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL2M3htFajtw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fraunfelder FT, Meyer SM. Sexual dysfunction secondary to topical ophthalmic timolol.<Emphasis Type="Italic">JAMA</Emphasis>. 1985;253:3092–3093.</BibUnstructured>
              </Citation>
              <Citation ID="CR43">
                <CitationNumber>43.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SJ</Initials>
                    <FamilyName>Sorensen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SR</Initials>
                    <FamilyName>Abel</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Comparison of the ocular beta-blockers</ArticleTitle>
                  <JournalTitle>Ann Pharmacother</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>43</FirstPage>
                  <LastPage>54</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8773166</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28Xht1aiurw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sorensen SJ, Abel SR. Comparison of the ocular beta-blockers.<Emphasis Type="Italic">Ann Pharmacother</Emphasis>. 1996;30:43–54.</BibUnstructured>
              </Citation>
              <Citation ID="CR44">
                <CitationNumber>44.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Schoene</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TR</Initials>
                    <FamilyName>Martin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NB</Initials>
                    <FamilyName>Charan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CL</Initials>
                    <FamilyName>French</FamilyName>
                  </BibAuthorName>
                  <Year>1981</Year>
                  <ArticleTitle Language="En">Timolol-induced bronchospasm in asthmatic bronchitis</ArticleTitle>
                  <JournalTitle>JAMA</JournalTitle>
                  <VolumeID>245</VolumeID>
                  <FirstPage>1460</FirstPage>
                  <LastPage>1461</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7206150</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1001/jama.245.14.1460</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL3M7ksFKhtg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schoene RB, Martin TR, Charan NB, French CL. Timolol-induced bronchospasm in asthmatic bronchitis.<Emphasis Type="Italic">JAMA</Emphasis>. 1981;245:1460–1461.</BibUnstructured>
              </Citation>
              <Citation ID="CR45">
                <CitationNumber>45.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Buskirk</FamilyName>
                    <Particle>Van</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RN</Initials>
                    <FamilyName>Weinreb</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DP</Initials>
                    <FamilyName>Berry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Lustgarten</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Podos</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MM</Initials>
                    <FamilyName>Drake</FamilyName>
                  </BibAuthorName>
                  <Year>1986</Year>
                  <ArticleTitle Language="En">Betaxolol in patients with glaucoma and asthma</ArticleTitle>
                  <JournalTitle>Am J Ophthalmol</JournalTitle>
                  <VolumeID>101</VolumeID>
                  <FirstPage>531</FirstPage>
                  <LastPage>534</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3706457</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Van Buskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM, Drake MM. Betaxolol in patients with glaucoma and asthma.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1986;101:531–534.</BibUnstructured>
              </Citation>
              <Citation ID="CR46">
                <CitationNumber>46.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LS</Initials>
                    <FamilyName>Harris</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SH</Initials>
                    <FamilyName>Greenstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AF</Initials>
                    <FamilyName>Bloom</FamilyName>
                  </BibAuthorName>
                  <Year>1986</Year>
                  <ArticleTitle Language="En">Respiratory difficulties with betaxolol</ArticleTitle>
                  <JournalTitle>Am J Ophthalmol</JournalTitle>
                  <VolumeID>102</VolumeID>
                  <FirstPage>274</FirstPage>
                  <LastPage>275</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3740189</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0002-9394(86)90157-1</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL283ptlWlug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1986;102:274–275.</BibUnstructured>
              </Citation>
              <Citation ID="CR47">
                <CitationNumber>47.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KE</Initials>
                    <FamilyName>Pfitzner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JG</Initials>
                    <FamilyName>Moffat</FamilyName>
                  </BibAuthorName>
                  <Year>1965</Year>
                  <ArticleTitle Language="En">Sulfoxide-carbodiimide reactions. I. A facile oxidation of alcohols</ArticleTitle>
                  <JournalTitle>J Am Chem Soc</JournalTitle>
                  <VolumeID>87</VolumeID>
                  <FirstPage>5661</FirstPage>
                  <LastPage>5670</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/ja00952a026</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaF28Xjs1WmsA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Pfitzner KE, Moffat JG, Sulfoxide-carbodiimide reactions. I. A facile oxidation of alcohols.<Emphasis Type="Italic">J Am Chem Soc</Emphasis>. 1965;87:5661–5670.</BibUnstructured>
              </Citation>
              <Citation ID="CR48">
                <CitationNumber>48.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1984</Year>
                  <ArticleTitle Language="En">The soft drug approach</ArticleTitle>
                  <JournalTitle>Chemtech</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>28</FirstPage>
                  <LastPage>38</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2cXls1OqsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N. The soft drug approach.<Emphasis Type="Italic">Chemtech</Emphasis>. 1984;14:28–38.</BibUnstructured>
              </Citation>
              <Citation ID="CR49">
                <CitationNumber>49.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Buchwald</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Soft drug design: general principles and recent applications</ArticleTitle>
                  <JournalTitle>Med Res Rev</JournalTitle>
                  <VolumeID>20</VolumeID>
                  <FirstPage>58</FirstPage>
                  <LastPage>101</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10608921</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/(SICI)1098-1128(200001)20:1&lt;58::AID-MED3&gt;3.0.CO;2-X</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXltFWqsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Buchwald P. Soft drug design: general principles and recent applications.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 2000;20:58–101.</BibUnstructured>
              </Citation>
              <Citation ID="CR50">
                <CitationNumber>50.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1989</Year>
                  <ChapterTitle Language="En">Designing safer ophthalmic drugs</ChapterTitle>
                  <BookTitle>Trends in Medicinal Chemistry ’88: Proceedings of the Xth International Symposium on Medicinal Chemistry</BookTitle>
                  <PublisherName>Elsevier</PublisherName>
                  <PublisherLocation>Amsterdam, The Netherlands</PublisherLocation>
                  <FirstPage>145</FirstPage>
                  <LastPage>164</LastPage>
                </BibChapter>
                <BibUnstructured>Bodor N. Designing safer ophthalmic drugs. In:<Emphasis Type="Italic">Trends in Medicinal Chemistry ’88: Proceedings of the Xth International Symposium on Medicinal Chemistry</Emphasis>. Amsterdam, The Netherlands: Elsevier; 1989:145–164.</BibUnstructured>
              </Citation>
              <Citation ID="CR51">
                <CitationNumber>51.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ChapterTitle Language="En">The use of retrometabolic drug design concepts in ophthalmic drug discovery</ChapterTitle>
                  <BibEditorName>
                    <Initials>IK</Initials>
                    <FamilyName>Reddy</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Ocular Therapeutics and Drug Delivery: A Multidisciplinary Approach</BookTitle>
                  <PublisherName>Technomic</PublisherName>
                  <PublisherLocation>Lancaster, PA</PublisherLocation>
                  <FirstPage>335</FirstPage>
                  <LastPage>361</LastPage>
                </BibChapter>
                <BibUnstructured>Bodor N. The use of retrometabolic drug design concepts in ophthalmic drug discovery. In: Reddy IK, ed.<Emphasis Type="Italic">Ocular Therapeutics and Drug Delivery: A Multidisciplinary Approach</Emphasis>. Lancaster, PA: Technomic; 1996:335–361.</BibUnstructured>
              </Citation>
              <Citation ID="CR52">
                <CitationNumber>52.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Albert</FamilyName>
                  </BibAuthorName>
                  <Year>1985</Year>
                  <BookTitle>Selective Toxicity: The Physico-Chemical Basis of Therapy</BookTitle>
                  <PublisherName>Chapman and Hall</PublisherName>
                  <PublisherLocation>London, UK</PublisherLocation>
                </BibBook>
                <BibUnstructured>Albert A.<Emphasis Type="Italic">Selective Toxicity: The Physico-Chemical Basis of Therapy</Emphasis>. London, UK: Chapman and Hall; 1985.</BibUnstructured>
              </Citation>
              <Citation ID="CR53">
                <CitationNumber>53.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Gillette</FamilyName>
                  </BibAuthorName>
                  <Year>1979</Year>
                  <ArticleTitle Language="En">Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds</ArticleTitle>
                  <JournalTitle>Drug Metab Rev</JournalTitle>
                  <VolumeID>10</VolumeID>
                  <FirstPage>59</FirstPage>
                  <LastPage>87</LastPage>
                  <Occurrence Type="PID">
                    <Handle>118860</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3109/03602537908993901</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaE1MXls12htbs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gillette JR. Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds.<Emphasis Type="Italic">Drug Metab Rev</Emphasis>. 1979;10:59–87.</BibUnstructured>
              </Citation>
              <Citation ID="CR54">
                <CitationNumber>54.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>GJ</Initials>
                    <FamilyName>Mannering</FamilyName>
                  </BibAuthorName>
                  <Year>1981</Year>
                  <ChapterTitle Language="En">Hepatic cytochrome P-450-linked drug-metabolizing systems</ChapterTitle>
                  <BibEditorName>
                    <Initials>B</Initials>
                    <FamilyName>Testa</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>P</Initials>
                    <FamilyName>Jenner</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Concepts in Drug Metabolism. Part B</BookTitle>
                  <PublisherName>Marcel Dekker Inc</PublisherName>
                  <PublisherLocation>New York, NY</PublisherLocation>
                  <FirstPage>53</FirstPage>
                  <LastPage>166</LastPage>
                </BibChapter>
                <BibUnstructured>Mannering GJ. Hepatic cytochrome P-450-linked drug-metabolizing systems. In: Testa B, Jenner P, eds.<Emphasis Type="Italic">Concepts in Drug Metabolism. Part B</Emphasis>. New York, NY: Marcel Dekker Inc; 1981:53–166.</BibUnstructured>
              </Citation>
              <Citation ID="CR55">
                <CitationNumber>55.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KO</Initials>
                    <FamilyName>Borg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Carlsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K-J</Initials>
                    <FamilyName>Hoffmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K-J</Initials>
                    <FamilyName>Jönsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Thorin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Wallin</FamilyName>
                  </BibAuthorName>
                  <Year>1975</Year>
                  <ArticleTitle Language="En">Metabolism of metoprolol-(<Superscript>3</Superscript>H) in man, the dog and the rat</ArticleTitle>
                  <JournalTitle>Acta Pharmacol Toxicol (Copenh)</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>125</FirstPage>
                  <LastPage>135</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaE2MXlt1Kjsb0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Borg KO, Carlsson E, Hoffmann K-J, Jönsson K-J, Thorin H, Wallin B. Metabolism of metoprolol-(<Superscript>3</Superscript>H) in man, the dog and the rat.<Emphasis Type="Italic">Acta Pharmacol Toxicol (Copenh)</Emphasis>. 1975;36:125–135.</BibUnstructured>
              </Citation>
              <Citation ID="CR56">
                <CitationNumber>56.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CG</Initials>
                    <FamilyName>Regardh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Johnsson</FamilyName>
                  </BibAuthorName>
                  <Year>1980</Year>
                  <ArticleTitle Language="En">Clinical pharmacokinetics of metoprolol</ArticleTitle>
                  <JournalTitle>Clin Pharmacokinet</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>557</FirstPage>
                  <LastPage>569</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7002420</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL3M%2FmsFKhtw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Regardh CG, Johnsson G. Clinical pharmacokinetics of metoprolol.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1980;5:557–569.</BibUnstructured>
              </Citation>
              <Citation ID="CR57">
                <CitationNumber>57.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Benfield</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SP</Initials>
                    <FamilyName>Clissold</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RN</Initials>
                    <FamilyName>Brogden</FamilyName>
                  </BibAuthorName>
                  <Year>1986</Year>
                  <ArticleTitle Language="En">Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders</ArticleTitle>
                  <JournalTitle>Durgs</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>376</FirstPage>
                  <LastPage>429</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00003495-198631050-00002</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL28XktVSjtrw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Benfield P, Clissold SP, Brogden RN. Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.<Emphasis Type="Italic">Durgs</Emphasis>. 1986;31:376–429.</BibUnstructured>
              </Citation>
              <Citation ID="CR58">
                <CitationNumber>58.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Oshiro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Loftsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Katovich</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Caldwell</FamilyName>
                  </BibAuthorName>
                  <Year>1984</Year>
                  <ArticleTitle Language="En">Soft drugs. 6. The application of the inactive metabolite approach for design of soft β-blockers</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>120</FirstPage>
                  <LastPage>125</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1016376003515</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Oshiro Y, Loftsson T, Katovich M, Caldwell W. Soft drugs. 6. The application of the inactive metabolite approach for design of soft β-blockers.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1984;1:120–125.</BibUnstructured>
              </Citation>
              <Citation ID="CR59">
                <CitationNumber>59.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>El-Koussi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Kano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MM</Initials>
                    <FamilyName>Khalifa</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Soft drugs. 7. β-Blockers for systemic and ophthalmic use</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>1651</FirstPage>
                  <LastPage>1656</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3398002</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm00403a028</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXlt1ymsrg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, El-Koussi A, Kano M, Khalifa MM. Soft drugs. 7. β-Blockers for systemic and ophthalmic use.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1988;31:1651–1656.</BibUnstructured>
              </Citation>
              <Citation ID="CR60">
                <CitationNumber>60.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>El-Koussi</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Novel ‘soft’ β-blockers as potential safe antiglaucoma agents</ArticleTitle>
                  <JournalTitle>Curr Eye Res</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>369</FirstPage>
                  <LastPage>374</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2897269</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3109/02713688809031786</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXktlWmt70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, El-Koussi A. Novel ‘soft’ β-blockers as potential safe antiglaucoma agents.<Emphasis Type="Italic">Curr Eye Res</Emphasis>. 1988;7:369–374.</BibUnstructured>
              </Citation>
              <Citation ID="CR61">
                <CitationNumber>61.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Polgar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Cardiac electrophysiologic effects of adaprolol maleate, a new β-blocker, in closed chest dogs</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>48</VolumeID>
                  <FirstPage>1519</FirstPage>
                  <LastPage>1528</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1673212</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0024-3205(91)90276-H</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXhsFKqs70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Polgar P, Bodor N. Cardiac electrophysiologic effects of adaprolol maleate, a new β-blocker, in closed chest dogs.<Emphasis Type="Italic">Life Sci</Emphasis>. 1991;48:1519–1528.</BibUnstructured>
              </Citation>
              <Citation ID="CR62">
                <CitationNumber>62.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>El-Koussi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Zuobi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Kovacs</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma</ArticleTitle>
                  <JournalTitle>J Ocul Pharmacol Ther</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <FirstPage>115</FirstPage>
                  <LastPage>122</LastPage>
                </BibArticle>
                <BibUnstructured>Bodor N, El-Koussi A, Zuobi K, Kovacs P. Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma.<Emphasis Type="Italic">J Ocul Pharmacol Ther</Emphasis>. 1996;12:115–122.</BibUnstructured>
              </Citation>
              <Citation ID="CR63">
                <CitationNumber>63.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CN</Initials>
                    <FamilyName>McGhee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Dean</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Danesh-Meyer</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Locally administered ocular corticosteroids: benefits and risks</ArticleTitle>
                  <JournalTitle>Drug Saf</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>33</FirstPage>
                  <LastPage>55</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11820911</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00002018-200225010-00004</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XisVagsbk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks.<Emphasis Type="Italic">Drug Saf</Emphasis>. 2002;25:33–55.</BibUnstructured>
              </Citation>
              <Citation ID="CR64">
                <CitationNumber>64.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AL</Initials>
                    <FamilyName>Buchman</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Side effects of corticosteroid therapy</ArticleTitle>
                  <JournalTitle>J Clin Gastroenterol</JournalTitle>
                  <VolumeID>33</VolumeID>
                  <FirstPage>289</FirstPage>
                  <LastPage>294</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11588541</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00004836-200110000-00006</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3MrktVSjug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Buchman AL. Side effects of corticosteroid therapy.<Emphasis Type="Italic">J Clin Gastroenterol</Emphasis>. 2001;33:289–294.</BibUnstructured>
              </Citation>
              <Citation ID="CR65">
                <CitationNumber>65.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Raizman</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Corticosteroid therapy of eye disease: fifty years later</ArticleTitle>
                  <JournalTitle>Arch Ophthalmol</JournalTitle>
                  <VolumeID>114</VolumeID>
                  <FirstPage>1000</FirstPage>
                  <LastPage>1001</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8694704</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK28zis1ajsw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Raizman M. Corticosteroid therapy of eye disease: fifty years later.<Emphasis Type="Italic">Arch Ophthalmol</Emphasis>. 1996;114:1000–1001.</BibUnstructured>
              </Citation>
              <Citation ID="CR66">
                <CitationNumber>66.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JE</Initials>
                    <FamilyName>Dickerson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Dotzel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AF</Initials>
                    <FamilyName>Clark</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Steroid-induced cataract: new perspectives from in vitro and lens culture studies</ArticleTitle>
                  <JournalTitle>Exp Eye Res</JournalTitle>
                  <VolumeID>65</VolumeID>
                  <FirstPage>507</FirstPage>
                  <LastPage>516</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9464184</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1006/exer.1997.0359</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXmslOnsL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspectives from in vitro and lens culture studies.<Emphasis Type="Italic">Exp Eye Res</Emphasis>. 1997;65:507–516.</BibUnstructured>
              </Citation>
              <Citation ID="CR67">
                <CitationNumber>67.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Heyns</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Koch</FamilyName>
                  </BibAuthorName>
                  <Year>1952</Year>
                  <ArticleTitle Language="De">Über die bildung eines aminozuckers aus<Emphasis Type="Italic">d</Emphasis>-fruktose und ammoniak</ArticleTitle>
                  <JournalTitle>Z Naturforsch [B]</JournalTitle>
                  <VolumeID>7B</VolumeID>
                  <FirstPage>486</FirstPage>
                  <LastPage>488</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaG3sXhvFGgsA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Heyns K, Koch W. Über die bildung eines aminozuckers aus<Emphasis Type="Italic">d</Emphasis>-fruktose und ammoniak.<Emphasis Type="Italic">Z Naturforsch [B]</Emphasis>. 1952;7B:486–488.</BibUnstructured>
              </Citation>
              <Citation ID="CR68">
                <CitationNumber>68.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bucala</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Fishman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Cerami</FamilyName>
                  </BibAuthorName>
                  <Year>1982</Year>
                  <ArticleTitle Language="En">Formation of covalent adducts between cortisol and 16α-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>79</VolumeID>
                  <FirstPage>3320</FirstPage>
                  <LastPage>3324</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6808508</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.79.10.3320</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL38XktFOmsbk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bucala R, Fishman J, Cerami A. Formation of covalent adducts between cortisol and 16α-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1982;79:3320–3324.</BibUnstructured>
              </Citation>
              <Citation ID="CR69">
                <CitationNumber>69.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Manabe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bucala</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Cerami</FamilyName>
                  </BibAuthorName>
                  <Year>1984</Year>
                  <ArticleTitle Language="En">Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts</ArticleTitle>
                  <JournalTitle>J Clin Invest</JournalTitle>
                  <VolumeID>74</VolumeID>
                  <FirstPage>1803</FirstPage>
                  <LastPage>1810</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6501572</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1172/JCI111599</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2MXktVWiug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts.<Emphasis Type="Italic">J Clin Invest</Emphasis>. 1984;74:1803–1810.</BibUnstructured>
              </Citation>
              <Citation ID="CR70">
                <CitationNumber>70.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bucala</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Gallati</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Manabe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Cotlier</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Cerami</FamilyName>
                  </BibAuthorName>
                  <Year>1985</Year>
                  <ArticleTitle Language="En">Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts</ArticleTitle>
                  <JournalTitle>Exp Eye Res</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>853</FirstPage>
                  <LastPage>863</LastPage>
                  <Occurrence Type="PID">
                    <Handle>4018168</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0014-4835(85)90130-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2MXkvVWrtbg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bucala R, Gallati M, Manabe S, Cotlier E, Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts.<Emphasis Type="Italic">Exp Eye Res</Emphasis>. 1985;40:853–863.</BibUnstructured>
              </Citation>
              <Citation ID="CR71">
                <CitationNumber>71.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RC</Initials>
                    <FamilyName>Urban</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Cotlier</FamilyName>
                  </BibAuthorName>
                  <Year>1986</Year>
                  <ArticleTitle Language="En">Corticosteroid-induced cataracts</ArticleTitle>
                  <JournalTitle>Surv Ophthalmol</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>102</FirstPage>
                  <LastPage>110</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3541262</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0039-6257(86)90077-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2sXhs1Cksw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Urban RC, Jr, Cotlier E. Corticosteroid-induced cataracts.<Emphasis Type="Italic">Surv Ophthalmol</Emphasis>. 1986;31:102–110.</BibUnstructured>
              </Citation>
              <Citation ID="CR72">
                <CitationNumber>72.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Noble</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KL</Initials>
                    <FamilyName>Goa</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Loteprednol etabonate: clinical potential in the management of ocular inflammation</ArticleTitle>
                  <JournalTitle>Bio Drugs</JournalTitle>
                  <VolumeID>10</VolumeID>
                  <FirstPage>329</FirstPage>
                  <LastPage>339</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXnsVWrsrw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation.<Emphasis Type="Italic">Bio Drugs</Emphasis>. 1998;10:329–339.</BibUnstructured>
              </Citation>
              <Citation ID="CR73">
                <CitationNumber>73.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JF</Initials>
                    <FamilyName>Howes</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Loteprednol etabonate: a review of ophthalmic clinical studies</ArticleTitle>
                  <JournalTitle>Pharmazie</JournalTitle>
                  <VolumeID>55</VolumeID>
                  <FirstPage>178</FirstPage>
                  <LastPage>183</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10756536</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXhvFajur4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2000;55:178–183.</BibUnstructured>
              </Citation>
              <Citation ID="CR74">
                <CitationNumber>74.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Buchwald</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ChapterTitle Language="En">Design and development of a soft corticosteroid, loteprednol etabonate</ChapterTitle>
                  <BibEditorName>
                    <Initials>RP</Initials>
                    <FamilyName>Schleimer</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>PM</Initials>
                    <FamilyName>O’Byrne</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>SJ</Initials>
                    <FamilyName>Szefler</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>R</Initials>
                    <FamilyName>Brattsand</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Inhaled Steroids in Asthma. Optimizing Effects in the Airways</BookTitle>
                  <PublisherName>Marcel Dekker</PublisherName>
                  <PublisherLocation>New York, NY</PublisherLocation>
                  <FirstPage>541</FirstPage>
                  <LastPage>564</LastPage>
                </BibChapter>
                <BibUnstructured>Bodor N, Buchwald P. Design and development of a soft corticosteroid, loteprednol etabonate. In: Schleimer RP, O’Byrne PM, Szefler SJ, Brattsand R, eds.<Emphasis Type="Italic">Inhaled Steroids in Asthma. Optimizing Effects in the Airways</Emphasis>. New York, NY: Marcel Dekker, 2002:541–564.</BibUnstructured>
              </Citation>
              <Citation ID="CR75">
                <CitationNumber>75.</CitationNumber>
                <BibUnstructured>Bodor N, inventor.<Emphasis Type="Italic">Stéroïds doux exerçant une activité antiinflammatoire (Steroids having antiinflammatory activity)</Emphasis>. Belgian patent BE889,563 (Internat Classif C07J/A61K). November 3, 1981.</BibUnstructured>
              </Citation>
              <Citation ID="CR76">
                <CitationNumber>76.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Varga</FamilyName>
                  </BibAuthorName>
                  <Year>1990</Year>
                  <ArticleTitle Language="En">Effect of a novel soft steroid on the wound healing of rabbit cornea</ArticleTitle>
                  <JournalTitle>Exp Eye Res</JournalTitle>
                  <VolumeID>50</VolumeID>
                  <FirstPage>183</FirstPage>
                  <LastPage>187</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2311680</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0014-4835(90)90229-N</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3cXhslanu7g%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Varga M. Effect of a novel soft steroid on the wound healing of rabbit cornea.<Emphasis Type="Italic">Exp Eye Res</Emphasis>. 1990;50:183–187.</BibUnstructured>
              </Citation>
              <Citation ID="CR77">
                <CitationNumber>77.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Druzgala</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Hochhaus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate</ArticleTitle>
                  <JournalTitle>J Steroid Biochem</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>149</FirstPage>
                  <LastPage>154</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0960-0760(91)90120-T</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXisVSrtr8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Druzgala P, Hochhaus G, Bodor N. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.<Emphasis Type="Italic">J Steroid Biochem</Emphasis>. 1991;38:149–154.</BibUnstructured>
              </Citation>
              <Citation ID="CR78">
                <CitationNumber>78.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Loftsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Metabolism, distribution, and transdermal permeability of a soft corticosteroid, loteprednol etabonate</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>1275</FirstPage>
                  <LastPage>1278</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1448425</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1015849132396</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38XmsVGkt74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Loftsson T, Wu W-M. Metabolism, distribution, and transdermal permeability of a soft corticosteroid, loteprednol etabonate.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1992;9:1275–1278.</BibUnstructured>
              </Citation>
              <Citation ID="CR79">
                <CitationNumber>79.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Hochhaus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L-S</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ratka</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs</ArticleTitle>
                  <JournalTitle>J Pharm Sci</JournalTitle>
                  <VolumeID>81</VolumeID>
                  <FirstPage>1210</FirstPage>
                  <LastPage>1215</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1491342</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/jps.2600811217</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXpsVGguw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hochhaus G, Chen L-S, Ratka A, et al. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1992;81:1210–1215.</BibUnstructured>
              </Citation>
              <Citation ID="CR80">
                <CitationNumber>80.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Murakami</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats—for safer treatment of gastrointestinal inflammation</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <FirstPage>869</FirstPage>
                  <LastPage>874</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7667192</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1016213121069</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXmtV2qu7g%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Murakami T, Wu W-M. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats—for safer treatment of gastrointestinal inflammation.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1995;12:869–874.</BibUnstructured>
              </Citation>
              <Citation ID="CR81">
                <CitationNumber>81.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Murakami</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Engel</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <FirstPage>875</FirstPage>
                  <LastPage>879</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7667193</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1016265105139</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXmtV2qu7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Wu W-M, Murakami T, Engel S. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1995;12:875–879.</BibUnstructured>
              </Citation>
              <Citation ID="CR82">
                <CitationNumber>82.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Monder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HL</Initials>
                    <FamilyName>Bradlow</FamilyName>
                  </BibAuthorName>
                  <Year>1980</Year>
                  <ArticleTitle Language="En">Cortoic acids: explorations at the frontier of corticosteroid metabolism</ArticleTitle>
                  <JournalTitle>Recent Prog Horm Res</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>345</FirstPage>
                  <LastPage>400</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6997944</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL3cXlvFyjur4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Monder C, Bradlow HL. Cortoic acids: explorations at the frontier of corticosteroid metabolism.<Emphasis Type="Italic">Recent Prog Horm Res</Emphasis>. 1980;36:345–400.</BibUnstructured>
              </Citation>
              <Citation ID="CR83">
                <CitationNumber>83.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1977</Year>
                  <ChapterTitle Language="En">Novel approaches for the design of membrane transport properties of drugs</ChapterTitle>
                  <BibEditorName>
                    <Initials>EB</Initials>
                    <FamilyName>Roche</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Design of Biopharmaceutical Properties Through Prodrugs and Analogs</BookTitle>
                  <PublisherName>Academy of Pharmaceutical Sciences</PublisherName>
                  <PublisherLocation>Washington, DC</PublisherLocation>
                  <FirstPage>98</FirstPage>
                  <LastPage>135</LastPage>
                </BibChapter>
                <BibUnstructured>Bodor N. Novel approaches for the design of membrane transport properties of drugs. In: Roche EB, ed.<Emphasis Type="Italic">Design of Biopharmaceutical Properties Through Prodrugs and Analogs</Emphasis>. Washington, DC: Academy of Pharmaceutical Sciences; 1977:98–135.</BibUnstructured>
              </Citation>
              <Citation ID="CR84">
                <CitationNumber>84.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1982</Year>
                  <ArticleTitle Language="En">Designing safer drugs based on the soft drug approach</ArticleTitle>
                  <JournalTitle>Trends Pharmacol Sci</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>53</FirstPage>
                  <LastPage>56</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0165-6147(82)91008-2</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL38XhtlGis7w%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N. Designing safer drugs based on the soft drug approach.<Emphasis Type="Italic">Trends Pharmacol Sci</Emphasis>. 1982;3:53–56.</BibUnstructured>
              </Citation>
              <Citation ID="CR85">
                <CitationNumber>85.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1983</Year>
                  <ChapterTitle Language="En">Soft drugs: strategies for design of safer drugs</ChapterTitle>
                  <BookTitle>Metabolisme et Conception Medicaments: Quo Vadis? Proceedings of Symposium at Montpellier, France; November 26–27, 1981</BookTitle>
                  <PublisherName>CLIN MIDY</PublisherName>
                  <PublisherLocation>Montpellier, France</PublisherLocation>
                  <FirstPage>217</FirstPage>
                  <LastPage>251</LastPage>
                </BibChapter>
                <BibUnstructured>Bodor N. Soft drugs: strategies for design of safer drugs.<Emphasis Type="Italic">Metabolisme et Conception Medicaments: Quo Vadis? Proceedings of Symposium at Montpellier, France; November 26–27, 1981</Emphasis>; Montpellier, France, CLIN MIDY; 1983. 217–251.</BibUnstructured>
              </Citation>
              <Citation ID="CR86">
                <CitationNumber>86.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Druzgala</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Regioselective O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17α-alkoxy, a 17α-(1’-alkoxyethyloxy), a 17α-alkoxymethyloxy, or a 17α-methylthiomethyloxy function</ArticleTitle>
                  <JournalTitle>Steroids</JournalTitle>
                  <VolumeID>56</VolumeID>
                  <FirstPage>490</FirstPage>
                  <LastPage>494</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1805463</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0039-128X(91)90008-J</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXmtlamu7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Druzgala P, Bodor N. Regioselective O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17α-alkoxy, a 17α-(1’-alkoxyethyloxy), a 17α-alkoxymethyloxy, or a 17α-methylthiomethyloxy function.<Emphasis Type="Italic">Steroids</Emphasis>. 1991;56:490–494.</BibUnstructured>
              </Citation>
              <Citation ID="CR87">
                <CitationNumber>87.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ChapterTitle Language="En">The application of soft drug approaches to the design of safer corticosteroids</ChapterTitle>
                  <BibEditorName>
                    <Initials>E</Initials>
                    <FamilyName>Christophers</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>AM</Initials>
                    <FamilyName>Kligman</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>E</Initials>
                    <FamilyName>Schöpf</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>RB</Initials>
                    <FamilyName>Stoughton</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs</BookTitle>
                  <PublisherName>Raven Press Ltd</PublisherName>
                  <PublisherLocation>New York, NY</PublisherLocation>
                  <FirstPage>13</FirstPage>
                  <LastPage>25</LastPage>
                </BibChapter>
                <BibUnstructured>Bodor N. The application of soft drug approaches to the design of safer corticosteroids. In: Christophers E, Kligman AM, Schöpf E, Stoughton RB, eds.<Emphasis Type="Italic">Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs</Emphasis>. New York, NY: Raven Press Ltd; 1988:13–25.</BibUnstructured>
              </Citation>
              <Citation ID="CR88">
                <CitationNumber>88.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Buchwald</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity</ArticleTitle>
                  <JournalTitle>Pharmazie</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <FirstPage>396</FirstPage>
                  <LastPage>404</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15212309</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXks1yku7w%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Buchwald P, Bodor N. Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2004;59:396–404.</BibUnstructured>
              </Citation>
              <Citation ID="CR89">
                <CitationNumber>89.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Buchwald</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">General linearized biexponential model for QSAR data showing bilinear-type distribution</ArticleTitle>
                  <JournalTitle>J Pharm Sci</JournalTitle>
                  <VolumeID>94</VolumeID>
                  <FirstPage>2355</FirstPage>
                  <LastPage>2379</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16200570</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/jps.20438</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXht1OgtbbL</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Buchwald P. General linearized biexponential model for QSAR data showing bilinear-type distribution.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 2005;94:2355–2379.</BibUnstructured>
              </Citation>
              <Citation ID="CR90">
                <CitationNumber>90.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Druzgala</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes</ArticleTitle>
                  <JournalTitle>Curr Eye Res</JournalTitle>
                  <VolumeID>10</VolumeID>
                  <FirstPage>933</FirstPage>
                  <LastPage>937</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1959381</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3109/02713689109020329</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK38%2FntVWnug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Druzgala P, Wu W-M, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.<Emphasis Type="Italic">Curr Eye Res</Emphasis>. 1991;10:933–937.</BibUnstructured>
              </Citation>
              <Citation ID="CR91">
                <CitationNumber>91.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Bodor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W-M</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits</ArticleTitle>
                  <JournalTitle>Curr Eye Res</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>525</FirstPage>
                  <LastPage>530</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1505197</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3109/02713689209001808</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK38zntV2rtA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodor N, Bodor N, Wu W-M. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.<Emphasis Type="Italic">Curr Eye Res</Emphasis>. 1992;11:525–530.</BibUnstructured>
              </Citation>
              <Citation ID="CR92">
                <CitationNumber>92.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GD</Initials>
                    <FamilyName>Novack</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Howes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Crockett</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MB</Initials>
                    <FamilyName>Sherwood</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Change in intraocular pressure during long-term use of loteprednol etabonate</ArticleTitle>
                  <JournalTitle>J Glaucoma</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>266</FirstPage>
                  <LastPage>269</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9713785</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1cznvFCjtQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate.<Emphasis Type="Italic">J Glaucoma</Emphasis>. 1998;7:266–269.</BibUnstructured>
              </Citation>
              <Citation ID="CR93">
                <CitationNumber>93.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Howes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GD</Initials>
                    <FamilyName>Novack</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Failure to detect systemic levels and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration</ArticleTitle>
                  <JournalTitle>J Ocul Pharmacol Ther</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>153</FirstPage>
                  <LastPage>158</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9572541</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXisFyhtr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Howes J, Novack GD. Failure to detect systemic levels and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.<Emphasis Type="Italic">J Ocul Pharmacol Ther</Emphasis>. 1998;14:153–158.</BibUnstructured>
              </Citation>
              <Citation ID="CR94">
                <CitationNumber>94.</CitationNumber>
                <BibUnstructured>
                  <Emphasis Type="Italic">Lotemax (Loteprednol Etabonate Ophthalmic Suspension 0.5%) [product monograph]</Emphasis>. Rochester, NY: Bausch &amp; Lomb Pharmaceuticals. 1998.</BibUnstructured>
              </Citation>
              <Citation ID="CR95">
                <CitationNumber>95.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Ilyas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CB</Initials>
                    <FamilyName>Slonim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GR</Initials>
                    <FamilyName>Braswell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Favetta</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Schulman</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Longterm safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis</ArticleTitle>
                  <JournalTitle>Eye Contact Lens</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>10</FirstPage>
                  <LastPage>13</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14722462</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/01.ICL.0000092071.82938.46</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Longterm safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.<Emphasis Type="Italic">Eye Contact Lens</Emphasis>. 2004;30:10–13.</BibUnstructured>
              </Citation>
              <Citation ID="CR96">
                <CitationNumber>96.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Szelenyi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Hermann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>U</Initials>
                    <FamilyName>Petzold</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Pahl</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Hochhaus</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate</ArticleTitle>
                  <JournalTitle>Pharmazie</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <FirstPage>409</FirstPage>
                  <LastPage>411</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15212311</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXks1yku7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Szelenyi I, Hermann R, Petzold U, Pahl A, Hochhaus G. Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2004;59:409–411.</BibUnstructured>
              </Citation>
              <Citation ID="CR97">
                <CitationNumber>97.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Szelenyi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Hochhaus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Heer</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways</ArticleTitle>
                  <JournalTitle>Drugs Today (Barc)</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>313</FirstPage>
                  <LastPage>320</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXktFClu7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Szelenyi I, Hochhaus G, Heer S, et al. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways.<Emphasis Type="Italic">Drugs Today (Barc)</Emphasis>. 2000;36:313–320.</BibUnstructured>
              </Citation>
              <Citation ID="CR98">
                <CitationNumber>98.</CitationNumber>
                <BibUnstructured>Bodor N, inventor.<Emphasis Type="Italic">Androstene derivatives</Emphasis>. US patent 5 981 517. November 9, 1999.</BibUnstructured>
              </Citation>
              <Citation ID="CR99">
                <CitationNumber>99.</CitationNumber>
                <BibUnstructured>Barton P, Laws AP, Page MI. Structure-activity relationships in the esterase-catalysed hydrolysis and transesterification of esters and lactones.<Emphasis Type="Italic">J Chem Soc, Perkin Trans 2</Emphasis>. 1994; 2021–2029.</BibUnstructured>
              </Citation>
              <Citation ID="CR100">
                <CitationNumber>100.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Miklós</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Magyar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>É</Initials>
                    <FamilyName>Kiss</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">28-Day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period</ArticleTitle>
                  <JournalTitle>Pharmazie</JournalTitle>
                  <VolumeID>57</VolumeID>
                  <FirstPage>142</FirstPage>
                  <LastPage>146</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11878192</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Miklós A, Magyar Z, Kiss É, et al. 28-Day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2002;57:142–146.</BibUnstructured>
              </Citation>
              <Citation ID="CR101">
                <CitationNumber>101.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Kurucz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Tóth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Németh</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166)</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>307</VolumeID>
                  <FirstPage>83</FirstPage>
                  <LastPage>92</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12893841</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.103.053652</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXnslGktLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kurucz I, Tóth S, Németh K, et al. Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166).<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2003;307:83–92.</BibUnstructured>
              </Citation>
              <Citation ID="CR102">
                <CitationNumber>102.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Kurucz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Németh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Mészáros</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, antiasthmatic steroid</ArticleTitle>
                  <JournalTitle>Pharmazie</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <FirstPage>412</FirstPage>
                  <LastPage>416</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15212312</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXks1yku7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kurucz I, Németh K, Mészáros S, et al. Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, antiasthmatic steroid.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2004;59:412–416.</BibUnstructured>
              </Citation>
              <Citation ID="CR103">
                <CitationNumber>103.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Jaffuel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Demoly</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Gougat</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Transcriptional potencies of inhaled glucocorticoids</ArticleTitle>
                  <JournalTitle>Am J Respir Crit Care Med</JournalTitle>
                  <VolumeID>162</VolumeID>
                  <FirstPage>57</FirstPage>
                  <LastPage>63</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10903220</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3cvisFCiug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jaffuel D, Demoly P, Gougat C, et al. Transcriptional potencies of inhaled glucocorticoids.<Emphasis Type="Italic">Am J Respir Crit Care Med</Emphasis>. 2000;162:57–63.</BibUnstructured>
              </Citation>
              <Citation ID="CR104">
                <CitationNumber>104.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Bhalay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Sandham</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Recent advances in corticosteroids for the treatment of asthma</ArticleTitle>
                  <JournalTitle>Curr Opin Investig Drugs</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>1149</FirstPage>
                  <LastPage>1156</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12211406</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXhsFOgtLc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bhalay G, Sandham DA. Recent advances in corticosteroids for the treatment of asthma.<Emphasis Type="Italic">Curr Opin Investig Drugs</Emphasis>. 2002;3:1149–1156.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
